Abstract

Mantle cell lymphoma (MCL) is an uncommon non-Hodgkin lymphoma with a heterogeneous natural history. Significant strides have been made in the management of MCL. Clinical follow-up exceeds a decade with long-term remission durations in some patients. Modern induction strategies employ rituximab; a cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)-like backbone; and cytarabine (in alternating or sequential regimens). However, bendamustine/rituximab therapy is challenging these induction strategies. The role of transplant is in clinical evolution. Up-front high-dose therapy and autologous stem cell transplant remains an attractive option for those with chemosensitive disease regardless of the induction regimen chosen, whereas this approach in the relapsed or refractory setting has not yielded long-term disease-free intervals. Reduced-intensity allogeneic stem cell transplant remains a viable option in those with relapsed or refractory MCL.

Original languageEnglish (US)
Pages (from-to)2-6
Number of pages5
JournalOncology (Williston Park, N.Y.)
Volume27
StatePublished - Oct 1 2013

Fingerprint

Mantle-Cell Lymphoma
Transplantation
Transplants
Stem Cells
Cytarabine
Vincristine
Prednisone
Natural History
Non-Hodgkin's Lymphoma
Doxorubicin
Cyclophosphamide
Therapeutics
Rituximab

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

The place of transplantation in mantle cell lymphoma. / Lunning, Matthew A; Armitage, James Olen.

In: Oncology (Williston Park, N.Y.), Vol. 27, 01.10.2013, p. 2-6.

Research output: Contribution to journalReview article

@article{371baae4f9e04036825ded93b050986a,
title = "The place of transplantation in mantle cell lymphoma",
abstract = "Mantle cell lymphoma (MCL) is an uncommon non-Hodgkin lymphoma with a heterogeneous natural history. Significant strides have been made in the management of MCL. Clinical follow-up exceeds a decade with long-term remission durations in some patients. Modern induction strategies employ rituximab; a cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)-like backbone; and cytarabine (in alternating or sequential regimens). However, bendamustine/rituximab therapy is challenging these induction strategies. The role of transplant is in clinical evolution. Up-front high-dose therapy and autologous stem cell transplant remains an attractive option for those with chemosensitive disease regardless of the induction regimen chosen, whereas this approach in the relapsed or refractory setting has not yielded long-term disease-free intervals. Reduced-intensity allogeneic stem cell transplant remains a viable option in those with relapsed or refractory MCL.",
author = "Lunning, {Matthew A} and Armitage, {James Olen}",
year = "2013",
month = "10",
day = "1",
language = "English (US)",
volume = "27",
pages = "2--6",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",

}

TY - JOUR

T1 - The place of transplantation in mantle cell lymphoma

AU - Lunning, Matthew A

AU - Armitage, James Olen

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Mantle cell lymphoma (MCL) is an uncommon non-Hodgkin lymphoma with a heterogeneous natural history. Significant strides have been made in the management of MCL. Clinical follow-up exceeds a decade with long-term remission durations in some patients. Modern induction strategies employ rituximab; a cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)-like backbone; and cytarabine (in alternating or sequential regimens). However, bendamustine/rituximab therapy is challenging these induction strategies. The role of transplant is in clinical evolution. Up-front high-dose therapy and autologous stem cell transplant remains an attractive option for those with chemosensitive disease regardless of the induction regimen chosen, whereas this approach in the relapsed or refractory setting has not yielded long-term disease-free intervals. Reduced-intensity allogeneic stem cell transplant remains a viable option in those with relapsed or refractory MCL.

AB - Mantle cell lymphoma (MCL) is an uncommon non-Hodgkin lymphoma with a heterogeneous natural history. Significant strides have been made in the management of MCL. Clinical follow-up exceeds a decade with long-term remission durations in some patients. Modern induction strategies employ rituximab; a cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)-like backbone; and cytarabine (in alternating or sequential regimens). However, bendamustine/rituximab therapy is challenging these induction strategies. The role of transplant is in clinical evolution. Up-front high-dose therapy and autologous stem cell transplant remains an attractive option for those with chemosensitive disease regardless of the induction regimen chosen, whereas this approach in the relapsed or refractory setting has not yielded long-term disease-free intervals. Reduced-intensity allogeneic stem cell transplant remains a viable option in those with relapsed or refractory MCL.

UR - http://www.scopus.com/inward/record.url?scp=84921862252&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921862252&partnerID=8YFLogxK

M3 - Review article

C2 - 25374998

AN - SCOPUS:84921862252

VL - 27

SP - 2

EP - 6

JO - Oncology

JF - Oncology

SN - 0890-9091

ER -